Melanoma Vaccines Show Promise
While immunotherapy has transformed way melanoma is treated, about half of patients still do not respond. Researchers are pursuing multiple strategies to understand why this happens and to develop strategies to jumpstart a response. One approach showing promise in early clinical trials, comes in the form of new personalized vaccines being developed by Ugur Sahin of Johannes Gutenberg-Universität Mainz and BioNTech.
What’s Next for the Microbiome in Melanoma?
We know that the billions of bacteria that live in our bodies can impact the way we respond to immunotherapy, but can we harness this help more patients respond these life-saving drugs?
This Engineer is Building a ‘Better’ Biopsy
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 20 March 2019 In Science
Biopsies are an important tool to determine if a mole or other lesion is cancerous. For most patients, the occasional biopsy is no big deal. However for patients facing multiple abnormal or otherwise ‘suspicious’ spots in highly visible places the prospect can be daunting. Dr. Jesse Wilson, an MRA-funded investigator, is an engineer on a mission to build a better biopsy.
Bronze Bodies and Black Lungs: Five Ways the Tanning and Tobacco Industries Use the Same Playbook
Dr. Alan Blum has crusaded against the tobacco industry for 30 years and now he's taking aim at the tanning industry. According to Blum, both the tobacco and tanning industries exploit people in similar ways, by targeting youth, downplaying their own corporate responsibility, infiltrating pop-culture, and indeed, by becoming prolific icons.
Fight Back Give Back with Clinical Trials
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 24 February 2019 In News, Science
When patients understand all of their options, including clinical trials, they can make informed decisions about their care. For many patients, clinical trials represent the best possible way to get access to cutting-edge treatment options.
Overcoming Targeted Therapy Resistance
Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.
It’s Not that Simple: Young Women and Melanoma
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 15 February 2019 In Prevention, Science
Article after article describes the ‘skyrocketing’ increases in melanoma among young women. While most are quick to point out the clear association between intentional tanning and skin cancer, few ever hint that there may be more to the story.
When Are Melanoma Patients Finished with Immunotherapy?
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 January 2019 In Melanoma Stories, Science, Treatment
For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? According to Dr. Jeffrey Weber and the data he presented at the European Society for Medical Oncology (ESMO) Congress late last year, the answer is maybe not.
Melanoma Treatment Advances – 2018 in Review
2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.
MRA Advisor & Grantee Dr. Allison Awarded Nobel Prize for Transforming Cancer Care
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 28 November 2018 In News, Science, Treatment
MRA Scientific Advisory Panel Member & Grantee Dr. Allison Awarded Nobel Prize for his pioneering research to harness the power of the immune system to attack cancer. His work in immunotherapy, which began in the 1990’s, was audacious at the time. It helped to mainstream an entirely new class of tools in the arsenal against cancer; joining the likes of chemotherapy, radiation, and surgery.